¿ Aclara Biosciences Inc., of Hayward, Calif., filed a lawsuit against Caliper Technologies Inc., of Mountain View, Calif., alleging infringement of U.S. patent No. 5,750,015. The patent concerns methods and devices for moving molecules by the application of electrical fields.
¿ Alfacell Corp., of Bloomfield, N.J., said it completed accrual of 152 patients in a Phase III trial of Onconase in patients with inoperable malignant mesothelioma. Preliminary survival results are expected later this year.
¿ Avant Immunotherapeutics Inc., of Needham, Mass., said data published in the April 15 issue of the Journal of Immunology showed its second-generation complement inhibitor, TP20, has enhanced anti-inflammatory effects and targets localized sites of vascular inflammation in animals. TP20, the product name for sCR1sLex, targeted injured lung tissue, resulting in reductions in vascular permeability and inflammation.
¿ BioChem Pharma Inc., of Laval, Quebec, said the European Union¿s Committee for Proprietary Medicinal Products recommended approval of Zeffix, an oral treatment for chronic hepatitis B. The European Commission will make a final determination.
¿ Cangene Corp., of Mississauga, Ontario, filed an investigational new drug application seeking permission to begin clinical trials in Canada of a recombinant human growth hormone product. The company hopes to develop the product as a treatment for children with abnormally short stature and to help speed recovery in elderly patients who have sustained bone fractures.
¿ Insite Vision Inc., of Alameda, Calif., signed an option agreement with the University of California for therapeutic rights to patents and applications in the area of the TIGR gene for glaucoma. Insite already has licensed diagnostic rights to those patents.
¿ SciClone Pharmaceuticals Inc., of San Mateo, Calif., was awarded a $517,000 grant from the Cystic Fibrosis Foundation for its ongoing Phase II study of CPX, a drug designed to target an underlying protein-associated defect that causes the disease in many patients.